We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
TG Therapeutics Inc | NASDAQ:TGTX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.41 | -2.50% | 16.01 | 16.00 | 16.22 | 17.00 | 15.96 | 16.75 | 4,804,428 | 00:59:49 |
1. Name and Address of Reporting Person * WEISS MICHAEL S | 2. Issuer Name and Ticker or Trading SymbolTG THERAPEUTICS, INC. [TGTX] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) CEO and President |
3. Statement for Issuer's Fiscal Year Ended (MM/DD/YYYY) | ||
4. If Amendment, Date Original Filed(MM/DD/YYYY) | 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form Filed by One Reporting Person ___ Form Filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
1.Title of Security (Instr. 3) | 2. Trans. Date | 2A. Deemed Execution Date, if any | 3. Trans. Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Amount | (A) or (D) | Price | ||||||||
COMMON STOCK (1) | 9/10/2020 | G | 525000 | D | $0 | 13909214 | D | |||
COMMON STOCK (2) | 9/25/2020 | G | 2500 | D | $0 | 13906714 | D | |||
COMMON STOCK (1) | 12/15/2020 | G | 834877 | D | $0 | 13071837 | D | |||
COMMON STOCK (2) | 12/15/2020 | G | 1700 | D | $0 | 13070137 | D | |||
COMMON STOCK (2) | 12/15/2020 | G | 200 | D | $0 | 13069937 | D | |||
COMMON STOCK (2) | 12/22/2020 | G | 200 | D | $0 | 13069737 | D | |||
COMMON STOCK (2) | 12/28/2020 | G | 1000 | D | $0 | 13068737 | D | |||
COMMON STOCK (2) | 12/28/2020 | G | 655 | D | $0 | 13068082 (3) | I | See Note 3 |
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (MM/DD/YYYY) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Beneficially Owned at End of Issuer's Fiscal Year (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
(A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Reporting Owners | |||||
Reporting Owner Name / Address | |||||
Director | 10% Owner | Officer | Other | ||
WEISS MICHAEL S 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK, NY 10014 | X | CEO and President |
Signatures | ||
/s/ Michael Weiss | 12/31/2020 | |
**Signature of Reporting Person | Date |
1 Year TG Therapeutics Chart |
1 Month TG Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions